SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications - Neurodegenerative

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: idos5/31/2008 7:21:57 AM
   of 448
 
Immune cells 'vacuum up' Alzheimer's clumps

[The beauty of this crazy idea is that it can be tested by already approved drugs.]

newscientist.com

18:00 30 May 2008 NewScientist.com by Alison Motluk

Debris-gobbling immune cells can be enticed into the brain to eat away the amyloid plaques associated with Alzheimer's disease, according to a study in mice.

The study suggests a promising new approach in the fight against Alzheimer's – and several drug candidates are already on pharmaceutical company shelves, waiting to be tried out.

Richard Flavell at Yale University in New Haven, Connecticut, and his colleagues created a double transgenic mouse, dubbed Tg2576-CD11c-DNR. One gene predisposed it to develop amyloid plaques in its brain that mimic Alzheimer's disease, while another blocked the activity of TGF-beta, a cytokine.

The researchers had expected the double-transgenic mice to do even more poorly than their single-transgenic Alzheimer's cagemates. But as the animals got to old age – about 18 months – the Tg2576-CD11c-DNR mice performed significantly better at traversing through various mazes. When the researchers examined their brains, they found up to 90% less amyloid.

For reasons that are not entirely clear, selectively blocking TGF-beta allowed macrophages, immune cells that ingest unwanted materials, to get across the blood brain barrier and into the brain. There, they feasted on amyloid plaques. "It was like a vacuum cleaner," says Flavell.

Several drug candidates already exist that are known to block TGF-beta in a similar way. It's too early to know if such a drug would be able to roll back the symptoms. "But even to reverse the decline would be an improvement," says Flavell.

Journal reference: Nature Medicine, DOI: 10.1038/nm1781
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext